^
    Back
    Association details:
    Biomarker:NFE2L2 mutation
    Cancer:Lung Cancer
    Drug:sapanisertib (CB-228) (mTORC1 inhibitor, mTORC2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

    Excerpt:
    ...- Patients must have histologically or cytologically confirmed stage IV or recurrent squamous cell lung cancer or KRAS mutant lung cancer that harbors any of the NFE2L2 mutations or KEAP1 mutations; any KEAP1 mutation will be eligible...
    Trial ID:
    NCT02417701
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

    Excerpt:
    ...Biomarker eligibility for S1900D is based on the identification of an NFE2L2 mutation or KEAP1 alteration...
    Trial ID:
    ECOG-ACRIN LUNG-MAP Sub-Study
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Thorac Oncol
    Title:

    Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228

    Published date:
    10/11/2022
    Excerpt:
    ...we describe specific potent activity of TAK-228, a TORC1/2 inhibitor, in NSCLC models harboring Nrf2 activating alterations, and results of a phase 2 clinical trial of TAK-228 in patients with advanced NSCLC harboring NRF2 activating alterations including 3 cohort...TAK-228 was most efficacious in a LUSC cohort with NFE2L2 alterations...
    DOI:
    https://doi.org/10.1016/j.jtho.2022.09.225